|Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment|
|Zheng, Xiaohui; Ding, Ning; Song, Yuqin; Feng, Lixia; Zhu, Jun|
|关键词||Germinal Center b Cell-like Diffuse Large b Cell Lymphoma Bruton&Prime s Tyrosine Kinase Bcr Apoptosis|
|刊名||CANCER CELL INTERNATIONAL|
|WOS标题词||Science & Technology|
|关键词[WOS]||CHRONIC LYMPHOCYTIC-LEUKEMIA ; BRUTON TYROSINE KINASE ; RITUXIMAB THERAPY ; PROTEIN-KINASE ; ACTIVATION ; SURVIVAL ; EXPRESSION ; INHIBITORS ; PCI-32765 ; MALIGNANCIES|
Background: Although rituximab in the combination of CHOP chemotherapy has been widely used as the standard treatment for several kinds of B-cell non-Hodgkin lymphoma (B-NHL), a great number of B-NHL patients treated with this immunotherapy still develop primary and secondary resistance. Recently Bruton′s tyrosine kinase (Btk) inhibitor ibrutinib showed promising therapeutic effect in relapsed/refractory CLL and B-cell NHL, which provided essential alternatives for these patients.
Methods: The proliferation and apoptosis induction of tumor cells were measured by cell viability assay and Annexin-V staining. Western Blotting analysis and real-time PCR were used to detect the expression level of target proteins and chemokines production.
Results: We demonstrated that ibrutinib inhibited the proliferation and induced apoptosis of GCB-DLBCL cell lines through suppression of BCR signaling pathway and activation of caspase-3. Furthermore, the chemokines CCL3 and CCL4 production from tumor cells were also found to be attenuated by ibrutinib treatment. But different cell lines exhibited distinct sensitivity after ibrutinib treatment. Interestingly, the decreasing level of p-ERK after ibrutinib treatment, but not the basal expression level of Btk, correlated with different drug sensitivity.
Conclusions: Ibrutinib could be a potentially useful therapy for GCB-DLBCL and the decreasing level of p-ERK could become a useful biomarker to predict related therapeutic response.
|项目编号||81201873 ; 81241073 ; 7132050|
|资助机构||NSFC ; Beijing Natural Science Foundation ; "985" Basic Research Fund from Peking University|
|作者单位||Peking Univ, Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China|
|Zheng, Xiaohui,Ding, Ning,Song, Yuqin,et al. Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment[J]. CANCER CELL INTERNATIONAL,2014,14.|
|APA||Zheng, Xiaohui,Ding, Ning,Song, Yuqin,Feng, Lixia,&Zhu, Jun.(2014).Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment.CANCER CELL INTERNATIONAL,14.|
|MLA||Zheng, Xiaohui,et al."Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment".CANCER CELL INTERNATIONAL 14(2014).|